Cargando…
EGFR突变非小细胞肺癌患者奥希替尼诱导间质性肺疾病后奥希替尼再挑战:病例报道
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607285/ https://www.ncbi.nlm.nih.gov/pubmed/34802213 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.39 |
Ejemplares similares
-
替吉奥胶囊导致的急性间质性肺病1例报道
Publicado: (2014) -
奥希替尼在非小细胞肺癌靶向治疗中的获得性耐药机制
Publicado: (2020) -
厄洛替尼致间质性肺病4例并文献复习
Publicado: (2012) -
阿来替尼治疗非小细胞肺癌患者发生间质性肺疾病再用克唑替尼治疗有效
Publicado: (2023) -
Polo样激酶1抑制剂在奥希替尼耐药的非小细胞肺癌细胞中的作用
Publicado: (2023)